<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F1494C6F-6E63-47EF-9F48-7FF52EB02450"><gtr:id>F1494C6F-6E63-47EF-9F48-7FF52EB02450</gtr:id><gtr:name>Autolus Limited</gtr:name><gtr:address><gtr:line1>c/o Syncona Partners LLP
215 Euston Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F1494C6F-6E63-47EF-9F48-7FF52EB02450" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F1494C6F-6E63-47EF-9F48-7FF52EB02450</gtr:id><gtr:name>Autolus Limited</gtr:name><gtr:address><gtr:line1>c/o Syncona Partners LLP
215 Euston Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>738893.0</gtr:offerGrant><gtr:projectCost>1231489.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>486954.0</gtr:offerGrant><gtr:projectCost>486954.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/71F84E62-65E5-4195-B08C-137A10DC4BAF"><gtr:id>71F84E62-65E5-4195-B08C-137A10DC4BAF</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Faulkner</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=104198"><gtr:id>323AB941-6070-4F1D-9DEA-8CF6379AD92B</gtr:id><gtr:title>Design, Transfer and Qualification of a Commercially-Scalable Process for Viral Vectors</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>104198</gtr:grantReference><gtr:abstractText>&amp;quot;Advanced Therapies have come of age. The spectacular clinical results demonstrated by novel gene-engineered T-cell therapies, with subsequent regulatory approvals in the US, have confirmed the commercial reality of a new class of therapeutics that offer real hope to patients who are bereft of effective treatment options. But behind this hope lies a deep concern that high cost-of-goods and problematical scalability will severely limit patient access to these therapies.

A critical component of these therapies is a recombinant viral vector capable of effectively transducing the T-cells and enabling the expression of novel anti-tumour receptors. Unfortunately, the current technologies to manufacture these vectors at commercial scales are not fit for purpose. This project will combine leading academic expertise and the commercial imperative of a UK Biotech company to create innovative and scalable viral vector processes that will facilitate patient access to Advanced Therapies.&amp;quot;</gtr:abstractText><gtr:fund><gtr:end>2021-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2018-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1225847</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">104198</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>